via University of Houston
Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, such as the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet – like a nasal vaccine – has been approved to provide mucosal immunity in the nose, the first barrier against the virus before it travels down to the lungs.
But now, we’re one step closer.
Navin Varadarajan, University of Houston M.D. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the development of an intranasal subunit vaccine that provides durable local immunity against inhaled pathogens.
“Mucosal vaccination can stimulate both systemic and mucosal immunity and has the advantagggggggggge of being a non-invasive procedure suitable for immunization of large populations,” said Varadarajan. “However, mucosal vaccination has been hampered by the lack of efficient delivery of the antigen and the need for appropriate adjuvants that can stimulate a robust immune response without toxicity.”
“Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2.”Navin Varadarajan, lead study author
To solve those problems, Varadarajan collaborated with Xinli Liu, associate professor of pharmaceutics at the UH College of Pharmacy, and an expert in nanoparticle delivery. Liu’s team was able to encapsulate the agonist of the stimulator of interferon genes (STING) within liposomal particles to yield the adjuvant named NanoSTING. The function of the adjuvant is to promote the body’s immune response.
“NanoSTING has a small particle size around 100 nanometers which exhibits significantly different physical and chemical properties to the conventional adjuvant,” said Liu.
“We used NanoSTING as the adjuvant for intranasal vaccination and single-cell RNA-sequencing to confirm the nasal-associated lymphoid tissue as an inductive site upon vaccination. Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2,” said Varadarajan.
“Equitable distribution requires vaccines that are stable and that can be shipped easily.”
A fundamental limitation of intramuscular vaccines is that they are not designed to elicit mucosal immunity. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses in the respiratory tract and the lung.
The nasal vaccine will also serve to equitably distribute vaccines worldwide, according to the researchers. It is estimated that first world countries have already secured and vaccinated multiple intramuscular doses for each citizen while billions of people in countries like India, South Africa, and Brazil with large outbreaks are currently not immunized. These outbreaks and viral spread are known to facilitate viral evolution leading to decreased efficacy of all vaccines.
“Equitable distribution requires vaccines that are stable and that can be shipped easily. As we have shown, each of our components, the protein (lyophilized) and the adjuvant (NanoSTING) are stable for over 11 months and can be stored and shipped without the need for freezing,” said Varadarajan.
Varadarajan is co-founder of AuraVax Therapeutics Inc., a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19. The company has an exclusive license agreement with UH with respect to the intellectual property covering intranasal vaccines and STING agonist technologies. They have initiated the manufacturing process and plan to engage the FDA later this year.
Original Article: IN THROUGH THE NOSE…
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Vaccine plea issued amid rise in cases of flu in north Wales hospitalson February 17, 2024 at 10:00 pm
Measles is highly contagious, and can spread very quickly amongst adults and children who are not vaccinated. Symptoms of measles include a high fever, a cough, runny nose, red watery eyes, a rash and ...
- Nasal vaccine for Alzheimer’s cuts atrophied brain matter in miceon February 15, 2024 at 4:00 pm
Scientists have developed a nasal Alzheimer's disease vaccine that they believe could be key to preventing and treating the degenerative cognitive condition in humans. The vaccine, which blocks a ...
- Could a nasal vaccine mean you never get Covid again? How it works, where to get one and everything you need to knowon February 15, 2024 at 4:02 am
This is not the only nasal vaccine in development – so could this really spell the end to Covid as we know it? So how does the new vaccine work? The vaccine is made of tiny spheres that ...
- Can Hong Kong play a leading role in creating longer-lasting flu vaccines? Researchers to join up with global experts and give it a shot, Post learnson February 13, 2024 at 2:36 am
Hong Kong medical researchers will be working with international experts to develop two vaccines that provide protection against more strains of influenza virus and also last longer, the Post has ...
- Ban of ineffective phenylephrine could affect access to other remedieson February 9, 2024 at 7:51 am
America's most popular cold medications contain a nasal decongestant that doesn't work, creating a knotty dilemma for regulators, a new study reports.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”nasal vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- USask Livestock and Forage Research Secures Nearly $6 Million Fundingon February 15, 2024 at 9:12 pm
Nineteen USask-led and four VIDO-led projects were provided funding by the ADF, which receives support from both the federal and provincial governments. Two additional projects at USask’s Prairie ...
- There’s a New Life-Saving Vaccine. Why Won’t People Take It?on February 14, 2024 at 4:11 pm
“Do I think this vaccine is great? I do,” she exclaims to her more than 158,000 followers. It’s an “absolutely wonderful thing,” and yes, she says, she’s gotten it herself. But she’s ...
- No evidence COVID-19 vaccine 'shuts off' the heart, contrary to anti-Kelce post | Fact checkon February 14, 2024 at 1:47 pm
"Mr. Pfizer showing you which organ the vaccine shuts off," reads text above the image. The post's caption reads, "He's telling you loud and clear! Remember to protect your HEART and say NO the ...
- Oral Vaccine Delivery: Can it Protect Against Non-mucosal Pathogens?on February 7, 2024 at 4:00 pm
The possibility of developing oral vaccines against non-mucosal pathogens is supported by studies with Japanese encephalitis and hepatitis B, which are transmitted by mosquito- and blood-borne ...
- New COVID Vaccine 54% Effective at Preventing Symptomson February 1, 2024 at 4:00 pm
Feb. 2, 2024 – If you’re in the minority of Americans who received the most recent COVID-19 vaccination, chances are you’re in the majority not experiencing any COVID symptoms now or in the ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”mucosal vaccination” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]